Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Overview of attention for article published in Cost Effectiveness and Resource Allocation, July 2017

Altmetric Badge

Mentioned by

So far, Altmetric has seen 2 X posts from 1 X users, with an upper bound of 2,181 followers.

Cost-effectiveness of interferon-free, direct-acting antiviral regimens f patients w #hepatitis C https://t.co/615li7CbHo #HCV

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with… https://t.co/CvdXQTz5SW https://t.co/tELX1mK9sd

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.